NervGen’s C$23 Million Bought Deal Financing

Paul Hastings LLP advised NervGen Pharma Corp. in the transaction.NervGen Pharma Corp. closed its public offering including the full exercise of the underwriters’ over-allotment option for…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Laura Testa

Author: Laura Testa

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here